Maja Beck‐Popovic

Interleukin 2 with anti-GD2 antibody ch14.18/CHO (dinutuximab beta) in patients with high-risk neuroblastoma (HR-NBL1/SIOPEN): a multicentre, randomised, phase 3 trial

Ruth Ladenstein, Ulrike Pötschger, Dominique Valteau‐Couanet et al. · The Lancet Oncology · 2018 · 401 citations

Life Sciences, Immunology, Oncology +8

Intravitreal chemotherapy for vitreous disease in retinoblastoma revisited: from prohibition to conditional indications

Francis L. Munier, Marie‐Claire Gaillard, Aubin Balmer et al. · British Journal of Ophthalmology · 2012 · 380 citations

Medicine, Oncology, Ophthalmology +17

Busulfan and melphalan versus carboplatin, etoposide, and melphalan as high-dose chemotherapy for high-risk neuroblastoma (HR-NBL1/SIOPEN): an international, randomised, multi-arm, open-label, phase 3 trial

Ruth Ladenstein, Ulrike Pötschger, Andrew D.J. Pearson et al. · The Lancet Oncology · 2017 · 348 citations · Full text

Medicine, Oncology, Pharmacology +8

Profiling safety of intravitreal injections for retinoblastoma using an anti-reflux procedure and sterilisation of the needle track

Francis L. Munier, Sameh E. Soliman, Alexandre Moulin et al. · British Journal of Ophthalmology · 2012 · 224 citations

Medicine, Oncology, Ophthalmology +16

Investigation of the Role of Dinutuximab Beta-Based Immunotherapy in the SIOPEN High-Risk Neuroblastoma 1 Trial (HR-NBL1)

Ruth Ladenstein, Ulrike Pötschger, Dominique Valteau‐Couanet et al. · Cancers · 2020 · 145 citations · Full text

Medicine, Oncology, Surgery +15